A prototype smart ring tracks multiple metabolic biomarkers in sweat, while Amazon One Medical launches Health Insights for blood biomarker analysis. Pharmacies are also using point-of-care testing to personalize supplement recommendations.
Eli Lilly's Taltz-Zepbound combination achieved significant improvements in two Phase 3b trials for plaque psoriasis and psoriatic arthritis with obesity. Combo therapy led to complete skin clearance and weight loss in psoriasis, and rapid disease activity reduction in psoriatic arthritis. The results were presented at AAD 2026.
FiberSense received CE marking for its optical CGM system with up to 28-day wear, while LifeScan partnered with i-SENS to launch the OneTouch Vita CGM and appointed a new CEO. Senseonics' year-long Eversense 365 implantable CGM is also detailed.
Diabetes technology companies Dexcom, Insulet, and Sequel/Senseonics announced major product launches and algorithm updates. Dexcom is acquiring Nutrisense and launching an enhanced Stelo app, Insulet is rolling out an updated Omnipod 5 algorithm with lower glucose targets and Abbott compatibility, and Sequel/Senseonics have fully launched the Eversense 365 CGM with the twiist insulin delivery system in the U.S.
Two studies reported mitochondrial mechanisms linked to diabetic wound repair, including targeted mitochondrial transplantation and the circular RNA circMTRNR2. The findings showed improved healing in experimental models and identified potential targets for chronic wound treatment.
InsideTracker's peer-reviewed PLOS Digital Health study of 20,000 users found sustained improvements across 39 blood biomarkers, including LDL, HbA1c, glucose, vitamin D, hsCRP and testosterone, linked to use of its personalized platform.
Evidence on ketogenic diets remains limited for psychiatric disorders and diabetes, while a systematic review in overweight and obese women with PCOS found significant short-term improvements. Experts said more controlled, long-term studies are needed.
Studies on immune checkpoint inhibitor therapy found pretreatment biomarkers strongly predicted checkpoint inhibitor-associated autoimmune diabetes, while hyperglycemia during treatment was common and did not worsen disease progression.
Wearable technologies are transforming clinical trials and healthcare with continuous monitoring capabilities, though clinical validation remains limited. While ECG features provide useful data for cardiac monitoring, many wearable metrics lack clinical accuracy and can cause patient anxiety. The technology shows promise for activity tracking and specific medical applications but requires cautious interpretation.
New research reveals metformin regulates blood sugar through brain pathways involving the Rap1 protein in the hypothalamus. The study shows suppressing Rap1 in the brain prevents metformin from lowering blood sugar in diabetic mice. These findings could lead to new diabetes treatments targeting this brain pathway.
